## CITATION REPORT List of articles citing

Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension

DOI: 10.1016/j.pupt.2008.07.003 Pulmonary Pharmacology and Therapeutics, 2008, 21, 824-32

Source: https://exaly.com/paper-pdf/44017355/citation-report.pdf

**Version:** 2024-04-03

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
61	PDE5 inhibitors in non-urological conditions. <i>Current Pharmaceutical Design</i> , <b>2009</b> , 15, 3521-39	3.3	24
60	Comparison of inhaled and intravenous milrinone in patients with pulmonary hypertension undergoing mitral valve surgery. <i>Advances in Therapy</i> , <b>2009</b> , 26, 462-8	4.1	66
59	Sildenafil for the treatment of pulmonary hypertension in pediatric patients. <i>Pediatric Cardiology</i> , <b>2009</b> , 30, 871-82	2.1	36
58	Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. <i>Journal of Hypertension</i> , <b>2010</b> , 28, 201-12	1.9	113
57	Prostacyclin in the intensive care setting. <i>Pediatric Critical Care Medicine</i> , <b>2010</b> , 11, S41-5	3	31
56	Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy. <i>Drug, Healthcare and Patient Safety</i> , <b>2010</b> , 2, 151-61	1.6	18
55	Inhaled treprostinil and pulmonary arterial hypertension. <i>Vascular Health and Risk Management</i> , <b>2010</b> , 6, 1115-24	4.4	6
54	Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2010</b> , 181, 270-8	10.2	210
53	Pharmacokinetic and hemodynamic responses to oral sildenafil during invasive testing in children with pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 1456-62	15.1	25
52	Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 1915-22	15.1	381
51	Medical and surgical treatment of acute right ventricular failure. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 56, 1435-46	15.1	136
50	Chronic thromboembolic pulmonary hypertension. Clinics in Chest Medicine, 2010, 31, 741-58	5.3	29
49	Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations. <i>Journal of Heart and Lung Transplantation</i> , <b>2010</b> , 29, 1210-7	5.8	37
48	The management of acute pulmonary arterial hypertension. Cardiovascular Therapeutics, 2011, 29, 153-	<b>7</b> 53	19
47	Clinical pharmacology and efficacy of inhaled iloprost for the treatment of pulmonary arterial hypertension. <i>Expert Review of Clinical Pharmacology</i> , <b>2011</b> , 4, 197-205	3.8	3
46	Acute effect of sildenafil is maintained in pulmonary arterial hypertension patients chronically treated with bosentan. <i>International Heart Journal</i> , <b>2011</b> , 52, 233-9	1.8	13
45	The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2011</b> , 5, 195-206	4.9	15

## (2016-2011)

44	Combination therapy in pulmonary arterial hypertension: do we have the right strategy?. <i>Expert Review of Respiratory Medicine</i> , <b>2011</b> , 5, 191-205	3.8	5
43	Pediatric pulmonary arterial hypertension: current and emerging therapeutic options. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 1845-64	4	3
42	Advances in the management of pediatric pulmonary hypertension. <i>Respiratory Care</i> , <b>2011</b> , 56, 1314-39; discussion 1339-40	2.1	32
41	Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 2583-93	4	7
40	Pulmonary vascular diseases. <i>Comprehensive Physiology</i> , <b>2011</b> , 1, 593-619	7.7	31
39	Inhaled treprostinil for the treatment of pulmonary arterial hypertension. <i>Expert Review of Respiratory Medicine</i> , <b>2012</b> , 6, 255-65	3.8	7
38	Optimal use of treprostinil in pulmonary arterial hypertension: a guide to the correct use of different formulations. <i>Drugs</i> , <b>2012</b> , 72, 2351-63	12.1	10
37	Inhaled treprostinil: a therapeutic review. <i>Drug Design, Development and Therapy</i> , <b>2012</b> , 6, 19-28	4.4	32
36	Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension. <i>Clinics in Chest Medicine</i> , <b>2013</b> , 34, 825-40	5.3	34
35	Pulmonary hypertension in chronic lung diseases. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, D109-16	15.1	390
34	Nonpulmonary influences on gas exchange. Comprehensive Physiology, 2014, 4, 1455-94	7.7	7
33	[Pulmonary hypertension in chronic respiratory diseases]. <i>Presse Medicale</i> , <b>2014</b> , 43, 945-56	2.2	1
32	Inhaled treprostinil sodium for pulmonary hypertension. Expert Opinion on Orphan Drugs, 2014, 2, 283-	<b>29:1</b> 1	
31	Prostanoid therapies in the management of pulmonary arterial hypertension. <i>Therapeutics and Clinical Risk Management</i> , <b>2015</b> , 11, 535-47	2.9	31
30	Chronic thromboembolic pulmonary arterial hypertension: a review of the literature and novel therapeutic approaches. <i>Expert Review of Respiratory Medicine</i> , <b>2015</b> , 9, 351-9	3.8	
29	Developments in pulmonary arterial hypertension-targeted therapy for chronic thromboembolic pulmonary hypertension. <i>Expert Review of Respiratory Medicine</i> , <b>2015</b> , 9, 559-69	3.8	3
28	Exercise pathophysiology and sildenafil effects in chronic thromboembolic pulmonary hypertension. <i>Heart</i> , <b>2015</b> , 101, 637-44	5.1	31
27	Safety and Tolerability of High-dose Inhaled Treprostinil in Pulmonary Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , <b>2016</b> , 67, 322-5	3.1	11

26	[Treatment of acute and chronic right ventricular failure]. <i>Medizinische Klinik - Intensivmedizin Und Notfallmedizin</i> , <b>2016</b> , 111, 463-80	3.2	1
25	Medical Therapy in Chronic Thromboembolic Pulmonary Hypertension. <i>Annals of the American Thoracic Society</i> , <b>2016</b> , 13 Suppl 3, S248-54	4.7	11
24	Update in treatment options in pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , <b>2016</b> , 35, 695-703	5.8	18
23	Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1. <i>Journal of Vascular Surgery</i> , <b>2016</b> , 64, 1468-1477	3.5	18
22	Tolerability and clinical efficacy of inhaled treprostinil in patients with group 1 pulmonary arterial hypertension. <i>Therapeutic Advances in Chronic Disease</i> , <b>2018</b> , 9, 171-177	4.9	2
21	Natural plant products in treatment of pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2018</b> , 8, 2045894018784033	2.7	16
20	Inhalation of repurposed drugs to treat pulmonary hypertension. <i>Advanced Drug Delivery Reviews</i> , <b>2018</b> , 133, 34-44	18.5	11
19	Cardiac Physiology and Pharmacology. <b>2019</b> , 424-457.e17		1
18	Pulmonary Hypertension. <b>2019</b> , 836-851.e14		
17	Advances in targeted therapy for chronic thromboembolic pulmonary hypertension. <i>Heart Failure Reviews</i> , <b>2019</b> , 24, 949-965	5	12
17 16		5	12
	Reviews, <b>2019</b> , 24, 949-965	5 3.3	12
16	Pharmacology of the Pulmonary Circulation. 2019, 165-179  Demographics and Outcomes of Pulmonary Hypertension Patients in United States Emergency		
16 15	Pharmacology of the Pulmonary Circulation. 2019, 165-179  Demographics and Outcomes of Pulmonary Hypertension Patients in United States Emergency Departments. Western Journal of Emergency Medicine, 2020, 21, 714-721  Does combination therapy work in chronic thromboembolic pulmonary hypertension?. IJC Heart	3.3	2
16 15 14	Pharmacology of the Pulmonary Circulation. 2019, 165-179  Demographics and Outcomes of Pulmonary Hypertension Patients in United States Emergency Departments. Western Journal of Emergency Medicine, 2020, 21, 714-721  Does combination therapy work in chronic thromboembolic pulmonary hypertension?. IJC Heart and Vasculature, 2020, 29, 100544  How should a physician approach the pharmacological management of chronic thromboembolic	3.3	2
16 15 14	Pharmacology of the Pulmonary Circulation. 2019, 165-179  Demographics and Outcomes of Pulmonary Hypertension Patients in United States Emergency Departments. Western Journal of Emergency Medicine, 2020, 21, 714-721  Does combination therapy work in chronic thromboembolic pulmonary hypertension?. IJC Heart and Vasculature, 2020, 29, 100544  How should a physician approach the pharmacological management of chronic thromboembolic pulmonary hypertension?. Expert Opinion on Pharmacotherapy, 2021, 22, 557-563	3.3	2
16 15 14 13	Pharmacology of the Pulmonary Circulation. 2019, 165-179  Demographics and Outcomes of Pulmonary Hypertension Patients in United States Emergency Departments. Western Journal of Emergency Medicine, 2020, 21, 714-721  Does combination therapy work in chronic thromboembolic pulmonary hypertension?. IJC Heart and Vasculature, 2020, 29, 100544  How should a physician approach the pharmacological management of chronic thromboembolic pulmonary hypertension?. Expert Opinion on Pharmacotherapy, 2021, 22, 557-563  Medicinal Plants Used in the Treatment of Pulmonary Hypertension. 2021, 317-339  Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and	3.3 2.4 4	2

## CITATION REPORT

8	Contemporary Pharmacotherapies Involving Nitric Oxide, Prostacyclin, and Endothelin Receptor Signaling Pathways. <b>2016</b> , 257-270		1
7	Prostacyclins. Handbook of Experimental Pharmacology, <b>2013</b> , 218, 177-98	3.2	4
6	Pharmacokinetics and tolerability of LIQ861, a novel dry-powder formulation of treprostinil. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020971509	2.7	4
5	Prostacyclin and Prostaglandins. <b>2011</b> , 1451-1463		
4	Pharmacology of the Pulmonary Circulation. <b>2011</b> , 133-142		
3	Right Heart Failure. <b>2014</b> , 311-329		
2	Pulmonary Hypertension in Intensive Care Units: An Updated Review. <i>Tanaffos</i> , <b>2019</b> , 18, 180-207	0.5	3
1	Group 3 Pulmonary Hypertension: From Bench to Bedside <i>Circulation Research</i> , <b>2022</b> , 130, 1404-1422	15.7	1